The effects of cycloastragenol on bovine embryo development, implantation potential and telomerase activity
Reproduction, Fertility and Development · 2023
DOI: 10.1071/rd22280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproduction, Fertility and Development, 2023. Verfasst von Abdul Majid Khan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju, Gyeongnam Province 52828, Republic of Korea. Hauptthemen laut MEDLINE: Telomerase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry, National Research Foundation of Korea.
Abstract (Originalsprache)
Context
Telomerase reverse transcriptase is a key factor responsible for structural and cellular alterations in aged oocytes and changes in the structure of the zona pellucida and mitochondria. Telomerase expression is reduced in aged cumulus oocyte complexes, and its activation or enhanced expression would be beneficial for in vitro oocyte maturation and in vitro embryo development.
Aims
This study aimed to investigate telomerase activation by cycloastragenol and its effect on bovine oocyte in vitro maturation, fertilisation, and early embryo development.
Methods
We used qPCR, Western blot, immunofluorescence, reactive oxygen species (ROS) assay,TUNEL assay, JC-1 assay, and invasion assay to analyse the affect of cycloastragenol (CAG) on bovine oocyte maturation, embryo development, embryo quality and implantation potential. Key results Cycloastragenol treatment of oocytes in in vitro maturation (IVM) media significantly (P < 0.05) improved oocyte IVM (90.87%), embryo cleavage (90.78%), blastocyst hatching (27.04%), and embryo implantation potential. Telomerase also interacts with mitochondria, and JC-1 staining results showed significantly (P < 0.05) higher mitochondrial membrane potential (??m) in the CAG-treated group. Furthermore, the inner cell mass (OCT4 and SOX2) and trophoblasts (CDX2) of the control and CAG groups were examined. Moreover, CAG treatment to primary cultured bovine cumulus cells substantially enhanced telomerase activity.
Conclusions
Telomerase activation via cycloastragenol is beneficial for bovine oocyte IVM and for the production of high-quality bovine embryos.
Implications
Cycloastragenol is a natural telomerase activator, and could be useful as a permanent component of oocyte maturation media.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju, Gyeongnam Province 52828, Republic of Korea.
- Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju, Gyeongnam Province 52828, Republic of Korea; and Institute of Agriculture and Life Science, Gyeongsang National University, Jinju, Gye…
- Department of Animal Science, Gyeongsang National University, Jinju, Republic of Korea.
Förderung
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry
- National Research Foundation of Korea
Zitieren
APA
Khan, A. M., Idrees, M., Perera, C. D., Haider, Z., Joo, M. D., Kang, J. S., Lee, S. H., & Kong, I. K. (2023). The effects of cycloastragenol on bovine embryo development, implantation potential and telomerase activity. Reproduction, Fertility and Development. https://doi.org/10.1071/rd22280
Vancouver
Khan AM, Idrees M, Perera CD, Haider Z, Joo MD, Kang JS, et al. The effects of cycloastragenol on bovine embryo development, implantation potential and telomerase activity. Reproduction, Fertility and Development. 2023. doi:10.1071/rd22280
BibTeX
@article{Khan2023,
author = {Khan, Abdul Majid and Idrees, Muhammad and Perera, Chalani Dilshani and Haider, Zaheer and Joo, Myeong-Don and Kang, Ji-Su and Lee, Seo-Hyeon and Kong, Il-Keun},
title = {The effects of cycloastragenol on bovine embryo development, implantation potential and telomerase activity},
journal = {Reproduction, Fertility and Development},
year = {2023},
doi = {10.1071/rd22280}
}
EUVIMED